Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GNLX Genelux	$3.78 +9.9%	$3.26	$1.95 ▼ $5.89	$142.78M	-0.32	87,582 shs	142,823 shs
RAPP Rapport Therapeutics	$14.77 -1.1%	$13.77	$6.43 ▼ $29.74	$539.08M	0.62	152,757 shs	182,176 shs
SNDL SNDL	$2.25 +0.4%	$1.57	$1.15 ▼ $2.40	$591.25M	3.57	4.67 million shs	2.49 million shs
ZVRA Zevra Therapeutics	$9.44 -0.7%	$10.56	$6.19 ▼ $13.16	$529.91M	1.87	1.63 million shs	1.21 million shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GNLX Genelux	+9.88%	+6.18%	+5.00%	+46.51%	+84.39%
RAPP Rapport Therapeutics	-1.07%	+0.48%	-4.71%	+36.51%	-34.27%
SNDL SNDL	+0.45%	+11.39%	+40.63%	+74.42%	+6.64%
ZVRA Zevra Therapeutics	-0.74%	+0.11%	-19.80%	+9.13%	+25.37%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
GNLX Genelux	1.5026 of 5 stars	3.6	2.0	1.6	0.0	0.0
RAPP Rapport Therapeutics	1.7168 of 5 stars	3.5	0.0	1.8	1.7	0.6
SNDL SNDL	1.757 of 5 stars	2.0	3.0	2.4	0.0	1.3
ZVRA Zevra Therapeutics	3.3944 of 5 stars	4.5	3.0	1.8	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GNLX Genelux	3.20	Buy	$17.75	369.58% Upside
RAPP Rapport Therapeutics	3.00	Buy	$29.50	99.73% Upside
SNDL SNDL	0.00	N/A	$4.00	77.78% Upside
ZVRA Zevra Therapeutics	3.00	Buy	$23.71	151.21% Upside

Current Analyst Ratings Breakdown

Latest GNLX, RAPP, SNDL, and ZVRA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/18/2025	ZVRA Zevra Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/13/2025	ZVRA Zevra Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
8/13/2025	ZVRA Zevra Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$19.00 ➝ $18.00
8/6/2025	RAPP Rapport Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$31.00
7/23/2025	GNLX Genelux	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
7/10/2025	ZVRA Zevra Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$25.00 ➝ $29.00
7/8/2025	RAPP Rapport Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$28.00
7/2/2025	ZVRA Zevra Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$26.00

(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GNLX Genelux	$10K	14,277.06	N/A	N/A	$0.63 per share	6.00
RAPP Rapport Therapeutics	N/A	N/A	N/A	N/A	$7.22 per share	N/A
SNDL SNDL	$671.81M	0.88	N/A	N/A	$2.99 per share	0.75
ZVRA Zevra Therapeutics	$23.61M	22.44	N/A	N/A	$2.09 per share	4.52

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GNLX Genelux	-$29.87M	-$0.86	N/A	N/A	N/A	N/A	-107.47%	-83.14%	N/A
RAPP Rapport Therapeutics	-$78.31M	-$2.50	0.00	N/A	N/A	N/A	-29.99%	-28.64%	11/6/2025 (Estimated)
SNDL SNDL	-$69.18M	-$0.27	0.00	N/A	N/A	-10.38%	-8.58%	-7.23%	11/4/2025 (Estimated)
ZVRA Zevra Therapeutics	-$105.51M	-$0.21	0.00	47.20	N/A	4.33%	-112.40%	-37.67%	11/11/2025 (Estimated)

Latest GNLX, RAPP, SNDL, and ZVRA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	GNLX Genelux	-$0.22	-$0.20	+$0.02	-$0.20	N/A	N/A
8/7/2025	Q2 2025	RAPP Rapport Therapeutics	-$0.87	-$0.75	+$0.12	-$0.75	N/A	N/A
7/31/2025	Q2 2025	SNDL SNDL	-$0.04	$0.01	+$0.05	$0.01	$231.50 million	$179.78 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
GNLX Genelux	N/A	N/A	N/A	N/A	N/A
RAPP Rapport Therapeutics	N/A	N/A	N/A	N/A	N/A
SNDL SNDL	N/A	N/A	N/A	N/A	N/A
ZVRA Zevra Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GNLX Genelux	N/A	4.18	4.18
RAPP Rapport Therapeutics	N/A	22.75	22.75
SNDL SNDL	0.11	5.03	3.36
ZVRA Zevra Therapeutics	0.52	7.85	7.81

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GNLX Genelux	37.33%
RAPP Rapport Therapeutics	N/A
SNDL SNDL	N/A
ZVRA Zevra Therapeutics	35.03%

Insider Ownership

Company	Insider Ownership
GNLX Genelux	8.80%
RAPP Rapport Therapeutics	13.57%
SNDL SNDL	N/A
ZVRA Zevra Therapeutics	2.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GNLX Genelux	10	37.77 million	34.45 million	Not Optionable
RAPP Rapport Therapeutics	N/A	36.50 million	31.55 million	N/A
SNDL SNDL	2,516	262.78 million	N/A	Optionable
ZVRA Zevra Therapeutics	20	56.13 million	54.79 million	Optionable

GNLX, RAPP, SNDL, and ZVRA Headlines

Recent News About These Companies

Zacks Research Downgrades Zevra Therapeutics (NASDAQ:ZVRA) to Hold

August 22 at 9:59 AM | marketbeat.com

Zevra Therapeutics (NASDAQ:ZVRA) Sees Strong Trading Volume Following Insider Buying Activity

August 22 at 2:47 AM | americanbankingnews.com

Zevra Therapeutics rumor highlighted in Betaville blog

August 21 at 2:56 PM | msn.com

Zevra Therapeutics gains amid takeover speculation

August 21 at 2:56 PM | msn.com

Zevra Therapeutics (NASDAQ:ZVRA) Director John Bode Buys 5,000 Shares

August 21 at 8:54 AM | insidertrades.com

Tourmaline Bio (NASDAQ:TRML) versus Zevra Therapeutics (NASDAQ:ZVRA) Head to Head Review

August 20 at 2:09 AM | americanbankingnews.com

Zevra Therapeutics (NASDAQ:ZVRA) Stock Price Up 4.4% - Should You Buy?

August 17, 2025 | marketbeat.com

Cantor Fitzgerald Brokers Lower Earnings Estimates for ZVRA

August 17, 2025 | marketbeat.com

Equities Analysts Offer Predictions for ZVRA Q3 Earnings

August 17, 2025 | marketbeat.com

Q3 EPS Forecast for Zevra Therapeutics Increased by Analyst

August 17, 2025 | marketbeat.com

HC Wainwright Has Bearish Estimate for ZVRA FY2027 Earnings

August 16, 2025 | marketbeat.com

Cantor Fitzgerald Brokers Cut Earnings Estimates for ZVRA

August 16, 2025 | americanbankingnews.com

Q3 EPS Estimate for Zevra Therapeutics Lifted by Analyst

August 16, 2025 | americanbankingnews.com

Zevra Therapeutics (ZVRA) Reports Q2 Loss, Tops Revenue Estimates (Revised)

August 15, 2025 | zacks.com

Zevra Therapeutics (NASDAQ:ZVRA) Shares Gap Down on Analyst Downgrade

August 15, 2025 | marketbeat.com

JMP Securities Lowers Zevra Therapeutics (NASDAQ:ZVRA) Price Target to $18.00

August 15, 2025 | marketbeat.com

JMP Securities Has Lowered Expectations for Zevra Therapeutics (NASDAQ:ZVRA) Stock Price

August 15, 2025 | americanbankingnews.com

Zevra Therapeutics (NASDAQ:ZVRA) Releases Quarterly Earnings Results, Misses Estimates By $0.71 EPS

August 14, 2025 | marketbeat.com

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) is Altium Capital Management LLC's Largest Position

August 14, 2025 | marketbeat.com

Zevra Therapeutics (NASDAQ:ZVRA) Shares Gap Down Following Analyst Downgrade

August 14, 2025 | americanbankingnews.com

Zevra Therapeutics Faces $58.7 Million Impairment Charge, Raising Concerns Over Financial Stability

August 14, 2025 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

GNLX, RAPP, SNDL, and ZVRA Company Descriptions

Genelux NASDAQ:GNLX

$3.78 +0.34 (+9.88%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$3.78 +0.01 (+0.13%)

As of 08/22/2025 06:38 PM Eastern

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer. The company is also developing V2ACT Immunotherapy for treating pancreatic cancer. Genelux Corporation has a licensing agreement with ELIAS Animal Health, LLC for V-VET1, a clinical stage animal health product candidate. The company was incorporated in 2001 and is headquartered in Westlake Village, California.

Rapport Therapeutics NASDAQ:RAPP

$14.77 -0.16 (-1.07%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$14.76 0.00 (-0.03%)

As of 08/22/2025 06:06 PM Eastern

Rapport Therapeutics Inc. is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc. is based in BOSTON.

SNDL NASDAQ:SNDL

$2.25 +0.01 (+0.45%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$2.24 -0.02 (-0.67%)

As of 08/22/2025 07:58 PM Eastern

SNDL Inc. engages in the production, distribution, and sale of cannabis products in Canada. The company operates through Liquor Retail, Cannabis Retail, Cannabis Operations, and Investments segments. It engages in the cultivation, distribution, and sale of cannabis for the adult-use and medical markets; sells wines, beers, and spirits through wholly owned liquor stores; and private sale of recreational cannabis through wholly owned and franchised retail cannabis stores. In addition, the company produces and distributes inhalable products, such as flower, pre-rolls, and vapes. It offers its products under the Top Leaf, Sundial Cannabis, Palmetto, and Grasslands brands. The company was formerly known as Sundial Growers Inc. and changed its name to SNDL Inc. in July 2022. SNDL Inc. was incorporated in 2006 and is headquartered in Calgary, Canada.

Zevra Therapeutics NASDAQ:ZVRA

$9.44 -0.07 (-0.74%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$9.56 +0.13 (+1.32%)

As of 08/22/2025 07:59 PM Eastern

Zevra Therapeutics, Inc. discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and Arimoclomol for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time